High iron needs and low-iron diets combine to make early childhood one of the highest risk periods for iron deficiency. Recommendations for iron supplementation for this age group have been based on positive effects on anemia and child development. In contrast, the evidence regarding growth and morbidity outcomes has been equivocal, with some evidence of risk. The new evidence from Nepal and Zanzibar is reviewed, and possible interpretations are discussed. The Zanzibar trial found significant adverse effects in the overall population with poor malaria services and substantial benefit to irondeficient children (the majority) in an area where access to treatments was provided. Cost-effectiveness analysis suggests that targeting supplements to iron-deficient children in Zanzibar may not increase costs (relative to universal supplementation) and would increase benefit. Operations research is needed to test this. We conclude with three options for maximizing the benefits and minimizing the risks of iron supplements.
Introduction
An objective of the World Health Organization (WHO) Technical Consultation held in Lyon, France, 12-14 June 2006 , was to review the safety, efficacy, and potential effectiveness of iron interventions for children in various environments, especially in areas with a high prevalence of malaria. This paper focuses on iron supplementation as an intervention strategy. We begin with a summary of the evidence that has led to current guidelines that recommend iron supplements for young children. We then summarize the new evidence provided by the Nepal and Zanzibar trials. Finally, we consider how to incorporate the new evidence into programmatic and research recommendations. As a part of the discussion, we present preliminary estimates of the cost-effectiveness of targeted iron supplementation as a potential programmatic strategy.
Evidence base for current recommendations High prevalence of iron deficiency in young children
Around one in four people in the world is iron deficient, with young children being at especially high risk [1] . The capacity of iron to participate in reduction and oxidation reactions and its essential role in oxygen transport in the body make it a critical nutrient within every tissue of the body, including the brain. Young children have expanding muscle mass and blood volume-two tissues that are especially rich in ironmaking them an age group with especially high iron needs. Unfortunately, the diets consumed by infants and toddlers typically consist of foods with relatively low iron content (e.g., breastmilk, starchy foods) and/ or foods containing iron of low bioavailability (e.g., vegetables, legumes). Thus, in many resource-constrained households, the iron needs of young children are nearly impossible to meet without fortification or supplementation strategies [2] . The high iron needs and low iron diets combine to make early childhood one of the highest risk periods for iron deficiency and iron-deficiency anemia.
This acute need for iron during the period of complementary feeding (6 to 24 months) is concurrent with developmental processes (cognitive and motor) that may be affected deleteriously by iron deficiency,
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Iron supplementation of young children especially if it is severe enough to cause anemia. Thus, at the time the Nepal and Zanzibar trials were designed, the policy context was summarized in the 1998 International Nutritional Anemia Consultative Group/United Nations Children's Fund/World Health Organization (INACG/UNICEF/WHO) Guidelines [3] and the more comprehensive United Nations Children's Fund/ United Nations University/World Health Organization (UNICEF/UNU/WHO) document [4] on which they were largely based. (A draft of the UNICEF/UNU/ WHO document published in 2001 was already available at the time that the 1998 Guidelines were written.) The 1998 Guidelines recommended that Where iron-fortified complementary foods are not widely and regularly consumed by young children, infants should routinely receive iron supplements in the first year of life. Where the prevalence of anemia in young children (6-24 months) is 40% or more, supplementation should continue through the second year of life. [3] , p. 20 The specific guidelines for children 6 to 24 months of age are shown in table 1. The major evidence in support of iron supplementation for this age group has been its positive effects on anemia and child development.
Benefits of iron supplements to prevent and treat anemia
Anemia has been an outcome of most iron-supplementation trials, and there is substantial evidence that iron supplementation is efficacious to prevent and treat anemia in young children [4] . We focus here on the evidence from malaria-endemic populations. Malaria itself is a major cause of anemia, especially in young children (see, for example WHO/UNICEF [5] ), and so it is reasonable to wonder whether iron supplements can improve hemoglobin concentration in the face of malaria, even if the children are also iron deficient. However, current evidence (summarized below) strongly demonstrates that iron supplementation is efficacious to raise hemoglobin in malariaendemic populations, presuming the population has a high prevalence of iron-deficiency anemia at the start. Although the postsupplementation hemoglobin values may remain relatively low in malarious populations compared with nonmalarious populations, the presupplementation values are also usually lower. Thus, although the magnitude of hemoglobin response (and anemia reduction) varies widely from study to study, the hemoglobin gain achieved is usually substantial in both malarious and nonmalarious settings.
A meta-analysis of hemoglobin outcomes from randomized trials of iron supplements was conducted in 1998 to address this question in P. falciparum malariaendemic populations. Eleven randomized, placebocontrolled trials were included in the meta-analysis, with the following conclusion:
There was an improvement in hemoglobin concentration in all trials where this outcome was examined. The degree of increase was highly variable, with eight of the trials showing mean increases of between 0.2 and 1.2 g/dL and three having increases of more than 2.5 g/dL. Overall, the effect of iron supplementation on hemoglobin was an increase of 1.25 g/dL (95% CI = 1.20-1.30, N = 11). In studies that reported an effect on severe anemia, the summary estimate was RR = 0.50 (95% CI = 0.45-0.54, N = 4). Only one study, in Tanzanian infants, reported the effect of iron supplementation on the incidence of severe anemia (hematocrit < 25%), and this was 28.8% (95% CI = 6.3-45.8) lower in the iron group. These hematologic changes are large and likely to confer substantial benefits to the health of populations. [6] , p. 2
Although the above analysis included only trials from malaria-endemic areas prior to 1998, inclusion of evidence from other environments and more recent evidence does not alter the inference that iron supplementation is efficacious to increase hemoglobin concentrations of young children where iron-deficiency anemia is prevalent [7] . As a global average, it is estimated that approximately 50% of the anemia in the world is caused by iron deficiency [1] .
Potential benefits to child development
The evidence that iron deficiency has deleterious concurrent and perhaps long-term effects on child cognition and behavior has been a compelling motivation for clinical and public health practice to prevent and treat anemia. The evidence for this has been the subject of several reviews [7, 8] , including the paper in this volume by Lozoff [9] . It is clear that iron-deficient children behave differently from their well-nourished peers and perform worse on cognitive tests. Recent supplementation trials provide substantial evidence that this connection is causal, at least in part. Although the long-term consequences of these deficits have not been proven, it is compelling to prevent adverse alterations in the well-being and mental and motor function of children due to malnutrition, whether or not those effects measurably persist for years. The recommendation to prevent and correct iron deficiency in young children has been largely motivated by this concern.
Potential effects on growth Numerous iron-supplementation trials in young children have assessed growth and morbidity as outcomes, with diverse results. With regard to growth, two recent and independent meta-analyses [10, 11] both yielded the same conclusion, namely, that the summary effect estimates from available trial data show no significant effect of iron supplements on the growth of children, either positive or negative. The 1998 INACG/WHO/ UNICEF Guidelines for the Use of Iron Supplements to Prevent and Treat Anemia [3] were written prior to these two meta-analyses, but the evidence base used to develop the 1998 guidelines, in a position consistent with this recent evidence, also did not assume that iron-supplementation programs would improve child growth.
The overall effect may, however, obscure significant effects that have been reported in certain contexts. Both recent meta-analyses of growth outcomes searched for differential effects in subgroups of studies defined by important population-defined characteristics. Both groups of authors found some variables of potential predictive interest; however, these were inconsistent between the two reports. Ramakrishnan et al. [10] found that growth responses tended to be better (but still statistically nonsignificant) in populations with more growth faltering at baseline and populations with more anemia at baseline. Sachdev et al. [11] did not confirm either of these findings, but instead reported that growth responses tended to be positive (and statistically significant) in population samples that were in developing countries (weight-for age outcome), malaria hyperendemic (weight-for-age and height-for-age outcomes), older than 5 years (weight-for-age, weight-forheight, and height-for age outcomes), and had less than weekly frequency of supplementation (height-for-age outcome). Growth responses tended to be negative (i.e., adverse, and statistically significant) in populations that were in developed countries (height-for-age outcome) and had durations of supplementation of more than 6 months (height-for-age). The general picture that emerges from the article by Sachdev et al. [11] is that for growth, the benefit-to-risk balance from iron supplementation will be most favorable when the recipients are at risk for iron deficiency and growth faltering (i.e., those in developing countries) and when the dose and duration of iron are kept relatively low.
Potential effects on morbidity, especially malaria
Iron supplementation has the potential to decrease infectious morbidity by correcting immune defects due to iron deficiency, and also has the potential to increase morbidity by creating an iron-rich environment within the host that is favorable to at least some pathogens. Up to the late 1990s, when the most recent WHO and UNICEF guidelines [3, 4] were written, the rhetoric about these potentially opposite effects of iron was highly varied, with some claiming that the control of iron deficiency (including the use of supplements) would enhance immune function in children and reduce their morbidity, to others claiming that iron-deficiency anemia was an adaptive and protective mechanism that prevents morbidity, especially where malaria is prevalent. See, for example, UNICEF/UNU/ WHO/MI [12] and Weinberg [13] for examples of these contrasting views.
The 1998 Guidelines did not explicitly engage this debate, as their purpose was to draw on previous WHO, UNICEF, and INACG recommendations to provide clear and simple recommendations to program planners. However, in drawing upon existing documents that recommend universal (untargeted) supplementation, the 1998 Guidelines assumed that oral low-dose iron supplements were practically safe, even in children who were not iron deficient and children who were exposed to many infectious pathogens. This position was consistent with documents published by INACG, UNICEF, and WHO from 1977 to 2001 [4-5, 12, 14, 15] . In sum, the 1998 Guidelines did not claim that iron supplements would reduce morbidity in populations with a high prevalence of iron-deficiency anemia, but they assumed that morbidity would not increase.
Since the 1998 Guidelines were published, there have been more systematic examinations of the evidence on whether iron supplements have positive, negative, or no effects on morbidity outcomes, especially in children and where malaria is prevalent.
The hypothesis that iron supplementation increases the risk of malarial illness is longstanding, and as the 1998 Guidelines became more widely disseminated, there was a recognized need to address this concern.
Within a year, a meta-analysis was carried out and a panel of experts was convened by INACG to review the evidence. The resulting consensus statement was published in 1999. Its primary conclusions were as follows:
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Iron supplementation of young children tine use of iron supplements for individuals living in communities at significant risk of iron deficiency. The available data from malaria-endemic regions indicate that the known benefits of iron supplementation are likely to outweigh the risk of adverse effects caused by malaria. The implication is, therefore, that oral iron supplementation should continue to be recommended in malarious areas where iron-deficiency anemia is prevalent. The subgroups that should be targeted for accelerated implementation of oral iron supplementation are pregnant women and young children, especially infants of low birthweight. At the time this statement was written (1999), there was concern among the panel that iron supplementation might indeed confer risk on some population subgroups. Their first research recommendation was to provide evidence on the question: "Are there identifiable subgroups in which the risks of adverse effect of iron supplementation are higher or lower than for the general population?"
In a comprehensive review shortly thereafter, Oppenheimer [16] highlighted the heterogeneity of results of oral iron supplementation trials in malaria-endemic populations, with five of nine studies that he reviewed showing increased rates of clinical malaria and four of eight studies showing increased rates of morbidity from other illnesses. None of the studies showed a reduction in infection with oral iron. His concluding recommendations on strategies to avoid harm in malarious regions included to avoid supplementing people with known compromised immunity, avoid high doses of iron, avoid peak seasons for malaria transmission, and avoid individuals with known hemoglobin AS and SS genotypes.
Gera and Sachdev [17] also carried out a systematic review of 28 randomized, controlled trials of iron supplementation and fortification and concluded that "Iron supplementation has no apparent harmful effect on the overall incidence of infectious illnesses in children, though it slightly increases the risk of developing diarrhea. " The authors gauged that this effect on diarrhea "would not have an important overall impact on public health. "
Most recently, Iannotti et al. [7] reviewed randomized, controlled trials of oral iron supplements to young children in developing countries. In a section that focused on malarial outcomes, they included seven trials, five of which found no effect of iron on outcomes and two of which found adverse effects. Of those that found adverse effects, one was the Zanzibar main trial reviewed in detail below, and the other was a treatment trial of Tanzanian children with severe malarial anemia (mean hemoglobin, 4.1 g/dL) [18] , in which the iron treatment was 40 mg daily, a level four to seven times the recommended daily allowance (RDA) for young children. In addition, Iannotti et al. did not include two recent trials that reported no adverse effects of iron on malarial outcomes in high malaria transmission areas in Kenya [19, 20] . Both of these trials were conducted in anemic children who were also provided enhanced malarial services.
It is apparent that the data are difficult to summarize neatly. Meta-analyses, although useful attempts to provide a comprehensive view of the evidence, may also yield diverse results, depending on the analysts' decisions about which studies to include, their attention to pooled versus stratified analyses, and which characteristics they consider for stratification. When trials have involved diverse study samples and interventions, it may not be wise to seek a summary estimate. With those caveats in mind, we present a summary of the evidence prior to the two recent supplementation trials [17] , alongside the new trial evidence (table 2). The meta-analysis by Gera and Sachdev [17] was used because it is recent (2002) and it provided estimates of iron intervention effects for specific diseases that were easy to tabulate and compare with the new evidence. It should be noted that they included trials of fortification and parenteral iron injection in their meta-analysis, so the results should not be interpreted as exactly pertaining to oral iron supplementation, which is the topic of this paper. Also, for malaria as an outcome, they used malaria infection confirmed by blood film, not clinical malaria episodes. For this reason, the effect estimate based on oral iron supplementation to young children from the INACG consensus statement [6] is included as well.
The estimates of effect for malaria from these metaanalyses prior to the Zanzibar trial were not statistically significant and were not far from 1.0. However, the body of evidence was very slim, with only two studies of oral iron supplementation in young children reporting clinical attack rates [21, 22] . Two more recently published trials in malaria-endemic areas of Kenya [19, 20] also showed no adverse effect of iron on the risk of clinical malaria attacks; both of these enrolled only anemic children, and one excluded children with hemoglobin SS genotype [19] . In one of these four studies, that of Menendez et al. [21] in Ifakara, Tanzania, the iron supplements were given from 2 to 6 months of age, a strategy that differs from current recommendations and that avoids iron supplementation during the peak age of malarial illness [23] . Also, in all of these studies, malaria diagnosis and treatment services were accessible to the study population. All of the studies were too small to estimate mortality outcomes, which were indeed few.
New evidence from the Nepal and Zanzibar trials

Review of the trials and their designs
Both the Nepal [24] and the Zanzibar [25] trials were designed to assess mortality rates in children provided daily oral supplements of zinc, iron plus folic acid (IFA), both, or placebo. Both trials used identical supplements, which were in the form of dispersible tablets in blister packs. The dosages of nutrients per daily tablet were 10 mg of zinc, 12.5 mg of iron, and 50 µg of folic acid. For infants under 12 months old, half tablets were given. Both trials began with a crosssectional cohort of children 1 to 35 months of age, and then recruited into the trial all babies born in the study communities when they reached 1 month of age. The Nepal trial was cluster-randomized, and the Zanzibar trial was randomized at the household level. The Zanzibar trial assessed hospitalizations as an additional outcome to mortality, whereas the Nepal trial did not because access to hospitals is extremely low in the study site. However, the Nepal trial ascertained morbidity episodes through active surveillance in two subsamples of children.
A further difference between the trial designs was that the Zanzibar trial included a substudy of about 3,200 children in whom baseline iron status and anthropometry was assessed. The children in this substudy were analyzed as a separate sample, whose outcomes were not included in the effect estimates of the overall trial. Although it was not an explicit aim, the children in the substudy were also provided with additional health services in an attempt to balance the benefits and burdens of study participation.
These trials were monitored by a joint data safety committee, which advised that both trials stop prior to their planned end dates. In the case of the Zanzibar trial, this advice was based on an excess rate of hospitalizations and mortality observed in the two IFA-containing treatment arms. Thus, the concern in the Zanzibar trial was for the safety of the participants enrolled in those arms of the trial. In the case of the Nepal trial, the observed risk ratio for the IFA-containing arms was very close to 1.0, with no possibility of detecting a statistically significant effect of the IFA supplements in a reasonable time period. Both trials continued field operations, with all children allocated to zinc or placebo.
After the decision to stop the IFA arms of the trials, the Zanzibar substudy dataset was also frozen, and the results for the IFA arm and the placebo arms were analyzed separately from the main study results. Although the substudy was too small to provide robust comparisons of mortality rates between groups, it was possible to examine group differences in the combined outcome of hospitalization or mortality. The inclusion of baseline iron status and anthropometry results in the substudy children allowed for subgroup analyses to test whether the adverse effects were more pronounced in subgroups of children defined by better or worse nutritional status at baseline. The Zanzibar substudy provides both an overall relative risk of hospitalizations plus mortality associated with IFA supplementation and evidence for subgroup effects that are both statistically significant and programmatically important. Children who were iron deficient or anemic at baseline experienced large and statistically significant benefits from IFA sup- 
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Iron supplementation of young children plementation relative to their placebo-supplemented peers. This finding was consistent for the outcomes of total hospitalizations or mortality and malaria-related adverse events. In contrast to iron status and anemia, baseline anthropometric findings did not modify the effect of IFA on these outcomes.
Morbidity results
With regard to diarrhea, the findings from Zanzibar and Nepal are consistent with each other and show no effect (table 2). The apparent small adverse effect on diarrhea from the prior meta-analysis of Gera and Sachdev [17] seems to be overruled by the recent and consistent evidence from both Zanzibar and Nepal. The effect on malaria illness in the Zanzibar main study differs from the previous studies, showing significant adverse effects. The IFA treatment group had a 16% increase (95% confidence interval [CI], 0% to 34%) in serious malaria leading to hospitalization or death. For cerebral malaria, there was a 32% (95% CI, 2% to 70%) excess risk in the IFA group. Although these results are divergent from those of the prior trials, the effect size for clinical malaria seen in Zanzibar (16%) falls within the rather wide confidence intervals of most of the other trials, which had much smaller sample sizes.
With regard to serious respiratory illness, the Nepal trial reported no significant effect of IFA on acute lower respiratory infections, which is consistent with the prior evidence. In the Zanzibar study, respiratory infections were grouped with other infections deemed not to be malaria-related; this group of infections was increased by IFA supplementation (excess risk, 25%; 95% CI, 1% to 53%). Oppenheimer has pointed out that malaria may actually be an underlying cause of severe respiratory infections in malaria-endemic populations [16] . This could explain the discrepancy in respiratory outcomes between the Nepal and Zanzibar studies.
In summary, the Nepal and Zanzibar trials add substantially to the relevant evidence base by providing trials of iron supplementation in line with current recommendations and in unselected populations, and because they were designed to ascertain severe morbidity outcomes. Although the Nepal study (conducted in a population with high infectious disease rates but essentially no malaria) supports the prior policy assumption of "no effect, " the Zanzibar trial demonstrates adverse effects that appear to be mainly attributable to malaria in a population where Plasmodium falciparum malaria transmission was intense and no effective control measures were in place (i.e., bednet usage was low, and diagnostic and treatment services were largely absent).
Mortality results
If we consider the Zanzibar substudy as a third and independent estimate of the effects of universal IFA supplementation (with or without zinc) on child survival outcomes, we have three estimates of effect, summarized in table 3. Although we have presented the substudy results alongside the main trial results, it should be recognized that if the substudy and main trial results from Zanzibar are combined, the resulting estimate for hospitalizations plus mortality (highly influenced by the very large main trial) approximates that of the main trial and remains statistically significantly greater than unity. However, it was the judgment of the investigators that the effects of IFA in the substudy were qualitatively different from those in the main trial and should be considered separately.
The three estimates are qualitatively different, with the Zanzibar main trial indicating an overall increase in hospitalizations and mortality, the Nepal trial showing no effect at all, and the Zanzibar substudy showing a sizable but statistically nonsignificant decrease in hospitalizations combined with mortality. There are several explanations for these disparate results that we may consider: » The differences are due to chance variation. There is a single underlying true relative risk, and we have in hand several estimates of this with overlapping confidence intervals. According to this explanation, the true relative risk for mortality (a weighted average of the individual estimates) would be greater than 1.0, but the confidence interval would include 1.0. Arguing against this interpretation is the compelling evidence on cause-specific adverse events from the Zanzibar trial, indicating significantly increased risks of malaria-and infection-related causes in the IFA-supplemented children. Malaria-related events were increased by 16% in each of the IFA arms (p ≤ .05 for each trial arm), and infection-related causes other than malaria were increased by 25% in the IFA arm (p = .04) and by 40% in the IFA plus zinc arm (p = .001). The Zanzibar trial provides a great deal of internal consistency for the hypothesis that universal IFA supplementation conferred harm to some children in the Zanzibar context. » There are true differences between the studies that are driven by the degree of malaria transmission, with greater malaria transmission conferring greater risk from IFA supplementation. This has been the prevailing explanation to date and the explanation favored by English and Snow [26] . It is consistent with the significant (16%) increase in malaria-related adverse events in the Zanzibar trial and with the understanding that malaria may contribute to the risk of other illnesses (e.g., acute respiratory illness) in malaria-endemic settings [16] . » There are true differences between the studies that are driven by the risk of death due to common infections, with less control of infectious diseases generally, not only malaria, conferring greater risk from IFA supplementation. This interpretation is consistent with the evidence from all three studies, as it appears that the risk of adverse events in the placebo group of the three study samples was highest in the Zanzibar main trial, intermediate in the Nepal study, and lowest in the Zanzibar substudy. » There are true differences between the studies that are driven by an unknown factor or set of factors. We cannot rule out the possibility that other unmeasured factors contribute to true differences in effects between these studies. It is useful to continue to bear in mind these and potentially other alternative explanations as we move ahead with applied research. However, the malaria explanation (the second explanation above) is most obvious and seems to have gained consensus.
Potential predictors of harm or benefit from the two main trials
In light of the potential for harm from universal IFA supplementation, at least in some contexts, it is compelling to search for potential predictors of harm or benefit that could be used to target iron supplementation to those in whom the risk-benefit ratio is very favorable. Both the Nepal and the Zanzibar studies explored age, sex, and duration of supplementation as potential predictors of benefits, with no significant results. In the Zanzibar substudy, a greater number of potential predictive variables were available. Anthropometric status, a known predictor of serious morbidity and mortality, did not modify the effect of IFA in Zanzibar. However, there was striking evidence that iron status did predict benefit (in the iron-deficient and anemic) and harm (in the non-iron-deficient).
In children with high zinc protoporphyrin (ZPP), an indicator that increases in iron-deficient erythropoiesis, the rate of adverse events (defined as hospitalization or mortality) was reduced by 38% (p = .02), and in children with low hemoglobin, the rate of adverse events was reduced by 41% (p = .02) relative to the their counterparts in the placebo group. When these two variables were cross-tabulated, children with both high ZPP and low hemoglobin had a 49% (p = .006) reduction in the risk of adverse events compared with their peers in the placebo group.
As predictors of harm from IFA supplementation, low ZPP predicted risk much more accurately than low hemoglobin, although the excess risk in neither subgroup was statistically significant. The excess risk of adverse events in the low-ZPP group was 63%, whereas the excess risk in the high-hemoglobin group was 8%. We have ample evidence from this [27] [28] [29] and previous studies in Zanzibar [5, 28] that ZPP and hemoglobin are strongly and inversely associated. Given that the low-ZPP group was considerably smaller than the high-hemoglobin group, it seems likely that the nonanemic group was an imperfect proxy for children with high ZPP.
Both low hemoglobin and high ZPP may have multiple underlying causes, although both are known to be strongly associated with iron deficiency. In this discussion, I will refer to high ZPP as "iron deficiency, " recognizing that this is not entirely accurate.
These subgroup results suggest that targeting IFA supplementation to children with high ZPP and/or low hemoglobin would be a means of preventing harm from IFA supplementation. The next section explores the option of targeting IFA supplementation based on the Zanzibar data. In doing so, we recognize that they are using some point estimates for relative risks (in the "iron-replete" groups) that are not statistically significant. However, given the policy dilemma that we find ourselves in, it seems prudent to make full use of the point estimates at hand.
First we address the potential motivations for targeting, which are shown to depend on the prevalence of iron deficiency or anemia. Second, we present preliminary estimates of the cost-effectiveness of targeting compared with universal supplementation in the Zanzibar context.
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Considerations of targeting iron supplements to iron-deficient children
Reasons to target
In the Zanzibar substudy, the overall number of adverse events per child-year was reduced by 24% in IFAsupplemented children, with a 95% confidence interval that ranged from a 48% reduction to a 9% increase. Given that IFA decreased adverse events only in the iron-deficient children, this overall 24% risk reduction is a function of the large risk reduction in irondeficient children (38% [95% CI, 7% to 59%]), the high prevalence of iron deficiency (76%). and the twofold higher absolute risk of adverse events in iron-deficient children compared with iron-replete children (9.76 vs. 4.83 adverse events per 100 child-years, p = .04) in children who were not supplemented with IFA (i.e., the placebo group rates). The third point is important and is easily missed in our focus on the relative risks associated with IFA supplements.
If we assume that the relative risks are constant, we can model the adverse events caused and prevented by universal IFA supplementation as a function of the prevalence of iron deficiency. We can predict the prevalence of iron deficiency below which the number of adverse events caused by IFA supplementation of replete children exceeds the number of adverse events prevented. This would occur when the prevalence of high ZPP is 45%. Above this point of crossover, universal IFA supplementation will reduce adverse events overall, even though it increases the risk in a subpopulation of children. This was the case in Zanzibar, with a 76% prevalence of high ZPP. When the prevalence of iron deficiency exceeds 45%, universal supplementation would be a rational choice at the population level, although some children would be harmed by it.
Targeting IFA supplementation to children with high ZPP is theoretically worth considering at any prevalence of iron deficiency, but the motivations differ. At a prevalence of 45% or less, universal supplementation does more harm than good. Targeting is necessary to achieve any overall benefit from the program in terms of hospitalizations and mortality. At prevalence rates greater than 45%, even a universal program would yield an overall benefit at the population level; however, targeting would avoid doing any (known) harm to any children and would increase the overall benefit of the program (by avoiding harm to iron-replete children).
Cost-effectiveness of universal versus targeted supplementation
Cost-effectiveness analyses provide a rational basis for choosing among child health interventions and among programmatic strategies for delivering them [30] . In the preceding section, we showed that targeted supplementation would theoretically save the most lives, although the benefits of targeting diminish as the prevalence of iron deficiency increases. At irondeficiency prevalence rates of 45% or less, there is no benefit from IFA supplementation without targeting. At iron-deficiency prevalence rates greater than 45%, the question becomes one of logistics and cost. Is it feasible to target, and if so, how costly would it be?
As a starting point for addressing this question, we provide a preliminary cost-effectiveness analysis of universal versus targeted IFA supplementation to prevent hospitalizations and mortality, using the Zanzibar substudy context as an example. The analysis was carried out by using TreeAge Pro Suite Version 6 software and spreadsheet calculations. The decision trees and other assumptions used for the analysis will be provided on request.
This analysis is meant to be illustrative of the issues involved. It only addresses the outcome of hospitalizations and mortality and does not account for the purported effects of iron supplementation on child development. Cost-effectiveness is dependent on many local factors and costs and is thus highly contextual. The scenario, costs, and resulting estimates need to be tested with our Zanzibari colleagues and ultimately through operations research in the field. However, accepting these caveats, we have found that the cost-effectiveness analysis provides several important insights.
Zanzibar substudy scenario
In building the scenario, we have mimicked as closely as possible the Zanzibar substudy that generated the estimates of effectiveness. Because this was a research study, the scenario for supplementation (i.e., supervised provision of a very high-quality daily supplement for 1 year) is certain to cost more than supplementation in a typical program. The cost of universal IFA supplementation used in this example is $8.34 per eligible child, driven by the relatively expensive supplements, the daily supplementation schedule with monthly contacts with mothers, and the long duration of supplementation (12 months). However, the high-quality supplementation regimen provided in the substudy may be essential to yield the results that were obtained.
Thus, the primary usefulness of this exercise is not to provide estimates of the absolute cost or cost-effectiveness of IFA supplementation, but to estimate the relative cost-effectiveness of targeted versus universal supplementation.
The intervention scenario was to add IFA supplementation onto the 9-month immunization contact, which has high coverage in Zanzibar. In the universal supplementation scenario, as in the research trial, all children are provided with 12 months of daily IFA supplements made by Nutriset (Malauney, France). Whereas the research study provided the tablets on a weekly basis, in this scenario we provide the tablets on a monthly basis through outreach workers who would be hired in addition to the existing primary health care unit (PHCU) staff.
In the targeted scenario, hematofluorometers (Aviv Biomedical) are provided for the measurement of ZPP, along with a new health technologist whose fulltime job would be to maintain and supervise these machines. This technologist is provided training by Aviv Biomedical to make most simple repairs. In the base scenario, the machines are fully depreciated in 2 years. At the 9 month immunization visit, the child would be tested by existing PHCU staff. If the ZPP value was less than 80 µmol/mol heme, the mother would receive affirmation of the child's iron status and brief nutrition counseling. If the value was 80 µmol/ mol heme or more, the mother would receive the first month's supply of IFA tablets and counseling about how to administer them.
In both scenarios, population numbers were taken from the 2002 Tanzania census [31] and immunization coverage rates were taken from the 2004 Demographic and Health Survey [32] . The probability that a screened child would get the appropriate treatment (IFA supplements or not) was assumed to be 75%, reflecting human error and random malfunction of the hematofluorometer. The probabilities of high ZPP, compliance with supplementation, and risk of adverse events (conditioned on ZPP result) were taken from the substudy results.
Under a "no intervention" scenario, no costs are incurred and no adverse events are prevented. The total number of children who would be eligible to encounter the program (i.e., to receive 9 months of EPI contact) is 11,350 per year, and they would be expected to have 972 adverse events in a 1-year period (the placebo group rate from the Zanzibar substudy). Relative to this, universal IFA supplementation implemented on the whole island of Zanzibar would avert 128 adverse events per year (hospitalizations or mortality) at a cost of $94,000 per year, for a cost-benefit ratio of $734.
Predictably, targeted IFA supplementation prevents more adverse events (169 adverse events), because the high-ZPP children benefit and the low-ZPP children are not supplemented and are therefore protected from harm. The interesting result is that targeted IFA supplementation costs $89,000, which is less than the universal program, yielding a cost-benefit ratio of $525 per adverse event averted.
Cost-effectiveness analysis is a tool for comparing tradeoffs in choosing among interventions or-as in this case-variants of an intervention (targeted or universal) [33] . The two supplementation strategies can also be compared with each other, to answer our primary question: Is targeting on ZPP a cost-effective choice relative to universal supplementation? However, in this case, targeting saves more lives at less cost.
Therefore, a cost-effectiveness ratio for this comparison cannot be calculated, and targeting is said to dominate universal supplementation.
Factors that favor targeting in this scenario
We found only one other example of the use of cost-effectiveness analysis to evaluate targeting of a child-survival intervention, which was vitamin A supplementation. Loevinsohn et al. [34] addressed the question whether targeting vitamin A supplementation to children of low weight-for-age would be cost-effective in the Philippines. Their motivation to consider targeting was the potential to increase the efficiency of the program by delivering the intervention only to children at highest risk for the outcome (i.e., mortality), using the targeting criterion of underweight. It is not surprising (from our current vantage point) that targeting was not cost-effective. In two scenarios, targeting increased the cost per death averted by two-to fourfold. This counterexample to our result serves to illustrate several important factors that influence the favorable result for targeting of IFA supplementation in the Zanzibar context.
First, the cost of the IFA supplementation is very high compared with vitamin A supplementation-at least six times higher. Vitamin A supplementation is so inexpensive that avoiding supplementing better-nourished children does not save much money-especially when you are already in contact with them to do the screening. In contrast, avoiding IFA supplementation to noniron-deficient children is a real savings. Second, the difference in benefit to high-ZPP versus low-ZPP children is very large: a 38% reduction versus a 63% increase. In contrast, the beneficial effect of vitamin A on mortality does not differ between underweight and normal-weight children. Furthermore, in the case of IFA the effect for children with low ZPP is actually a dis-benefit. That is, if they are included in the program, they contribute excess adverse events.
Third, the risk of adverse events for children with high ZPP apart from IFA supplementation was two times higher than for children with low ZPP in the Zanzibar example. Thus, the benefit from IFA supplementation is reaching the children at highest risk for adverse outcome. This factor is actually similar to the vitamin A example, since underweight children also have higher mortality rates; indeed, this is what motivated the Philippines study. However, the difference was not as great in the vitamin A example (i.e., being iron deficient was a stronger risk factor for adverse events in Zanzibar than being underweight is for mortality).
A fourth factor is the cost of targeting. The cost of targeting was relatively low in both examples, although measuring weight is less expensive than measuring ZPP. Routine screening of ZPP has not been carried out in resource-poor settings, and our cost assump-
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Iron supplementation of young children tions need to be carefully evaluated and field tested. Routine screening of ZPP was carried out in the past in US pediatric settings for the purpose of detecting lead-exposed children [35] . Indeed, the use of ZPP as a screening indicator in pediatric practice was what motivated the development of relatively simple and portable hematofluorometers (Ray Yip, personal communication). However, as the Centers for Disease Control (CDC) blood lead level of concern decreased in the 1980s and 1990s, ZPP failed to be sensitive enough to detect the children at risk for low lead exposure, and it is no longer used for this purpose [36] .
We based our cost estimate on the use of the Aviv hematofluorometer (Aviv Biomedical, Inc., Lakewood NJ) the same instrument used in the Zanzibar research. The measurement is made from a whole drop of fresh blood, which is placed on a cover glass and inserted directly into the machine. A digital display of the measured value is produced within seconds. An advantage of this indicator is that is unaltered by blood-sampling techniques, because the measurement is not expressed per volume but rather per mole of heme. The instrument, however, has several disadvantages, including that it currently requires an electrical power supply (we included generator costs in our cost analysis), it requires rather expensive calibrating solutions with short shelf-life, and it is not designed to be robust to field settings. For this reason, we included the USbased training of a dedicated lab technologist in our cost scenario.
Sensitivity analysis
The relative importance of several cost factors was explored in sensitivity analyses, in which we a) added another backup hematofluorometer, b) decreased the life span of the hematofluorometers to 1 year (from 2 years), c) reduced the price of iron supplements (from US$0.029 to US$0.020 each), and d) increased coverage from 75% to 85%. Each of these variations made targeting less cost-effective, but in all cases, targeting still dominated universal supplementation. Of these factors, the price of the supplements was most influential. When b), c), and d) were modeled simultaneously, universal supplementation became more cost-effective, but by a very slim margin (US$19 per adverse event prevented).
Generalizability of this scenario
It is important to keep in mind that this scenario is based on only one substudy, in which mortality and hospitalizations were lower in IFA-supplemented children than in placebo-supplemented children. This protective relative risk was substantial, although not statistically significant, and was qualitatively different from the overall relative risk in the main trial (see table 1 ). As stated above, the explanation for this difference in overall effect of IFA is unknown, but it might be due to the enhanced provision of health services in the substudy communities. If so, it is important to understand the context in which these results were obtained and how they compare to contemporary contexts in Zanzibar and elsewhere.
The enhanced care provided by the researchers in the Zanzibar substudy consisted of provision of free antimalarial treatments and, for part of the study duration, antibiotics to children who sought care from the study supervisors. During the substudy period, 487 courses of sulfadoxine-pyrimethamine were provided for confirmed cases of malaria [25] over approximately 3,200 child-years. Insecticide-treated bednets were not provided by the study and were not widely in use at the time.
In recent years, malaria programs in sub-Saharan Thus, the malaria control situation in Zanzibar and throughout sub-Saharan Africa is highly dynamic. The malaria situation during the main trial, when the malaria control program was weak, is no longer generalizable to the current situation in Zanzibar, which appears to have improved measurably. It will be necessary to think carefully about how to integrate iron interventions with malaria-control strategies in this rapidly changing context.
Ethical considerations in targeting
A final but important note about our cost-effectiveness analysis of targeting is that we valued all adverse events equally, whether prevented by IFA supplementation or caused by IFA supplementation. This is reasonable from a purely cost perspective, but depending on one's ethical perspective, one might view a death from other causes in the absence of iron supplementation differently from a death attributable to IFA supplementation as a public health intervention. Many public health interventions confer risk to a minority while providing net benefit to the population as a whole (e.g., folic acid fortification [37] ). Indeed, our knowledge and ability to predict harm to population subgroups is likely to increase rapidly as genetic testing becomes more common in population research. An ethical framework for this needs to be considered, especially in resourcepoor settings where the costs and logistics of screening are most likely to be barriers.
For this specific example, based on the Zanzibar scenario, targeting is cost-effective (relative to universal supplementation) and also removes any ethical dilemma. The prevalence of high ZPP in Zanzibari children is high (76%); targeting will be even more cost-effective (relative to universal supplementation) in populations with less prevalent iron deficiency.
Concluding thoughts
Finally, we conclude by summarizing the strategies that could be considered as means of maximizing the benefit and minimizing the risk of iron-supplementation programs where infectious diseases (including malaria) are highly prevalent.
Restrict universal supplementation to populations with very high prevalence of iron deficiency, coupled with moderate to low rates of infectious illness and/or reasonably good and widely accessed curative services
The current recommendation for universal iron supplementation if the prevalence of anemia is greater than 40% [3, 4] now seems too low and too nonspecific to iron deficiency as a general recommendation. Until we more fully understand the biological basis for excess risk observed in the Zanzibar main trial, we should carefully consider universal iron supplementation even in populations similar to Nepal, where there was no excess risk at the population level. Current ironsupplementation programs are motivated by concern for children's well-being and development, rather than reductions in severe infectious morbidity. However, we would expect the benefits to those outcomes to be concentrated in the iron-deficient children as well. The challenge in changing policy along these lines is how to provide useful guidelines on the basis of rather scant evidence from a wide variety of contexts.
Deliver iron supplements with IPTi (intermittent presumptive treatment for infants) and other malaria-control interventions (e.g., enhanced curative services) where malaria is endemic
The findings from Zanzibar suggest that the risks of IFA supplementation are mitigated if the children are relatively protected from malaria-or at least its more severe clinical consequences-through provision of curative drugs. There is now a consortium of researchers in sub-Saharan Africa conducting trials of IPTi, which is the provision of intermittent presumptive treatment doses of antimalarial drugs to infants through EPI contacts [38] . The original study on IPTi (which did not utilize EPI contacts) was a 2 × 2 factorial of iron supplementation from 8 to 24 weeks and provision of presumptive treatments throughout infancy [21] . In that study, the iron-supplemented children did not have an excess risk of clinical malaria in infancy, and the incidence of severe anemia was decreased by 29% (95% CI, 6% to 46%) in late infancy (the peak period). Of the five IPTi trials completed or under way, two have incorporated universal iron supplementation. One in Tanzania provided daily iron supplementation from 8 to 24 weeks of age, and the other provided 1-month periods of iron supplementation at each of the 3 EPI + IPTi contacts (at 2, 4, and 9 months of age).
The concept of providing iron supplements during periods when infants are relatively protected from malaria (e.g., by maternal antibodies during the first half of infancy or along with IPTi) is supported by the plasma iron measurements published by Menendez et al. from the original IPTi trial [39] , in which infants were also randomly assigned to receive iron or no iron. Iron-supplemented infants had significantly higher plasma iron at 5 months of age, when iron supplements were being administered, but not at 8 or 12 months of age, after supplementation had stopped. This is of interest if we assume that plasma iron is the body pool of iron that is most available to pathogens such as Plasmodium. In contrast, plasma ferritin concentrations and hematological parameters (mean cell hemoglobin and severe anemia) were significantly improved throughout the second half of infancy in those who had been iron supplemented.
Target iron supplementation to children with high ZPP and/ or low hemoglobin
The analyses presented above suggest that targeting deserves further scrutiny, including operations research in the field to refine cost and feasibility estimates. Compared with the provision of universal (untargeted) supplements through public health programs, targeting supplements to iron-deficient children may increase benefits, decrease risks, save cost, and possibly heighten the awareness of iron deficiency on the part of health care workers and families. This optimism needs, however, to be tested in the field.
In the end, we must face the reality that iron-supplementation programs for young children have not been widely implemented, even when the "simple" strategy of universal supplementation was recommended. It is our observation that where programs have been implemented (using through home-added fortificants or oral supplements), they have been carried out in settings with relatively high functioning health systems and/ or intensive involvement of nongovernmental organizations. This is because daily (and even weekly) supplementation is a relatively system-intensive and costly intervention to implement. Where health systems have S583 Iron supplementation of young children the capacity to implement universal supplementation, they might be able to implement a targeted strategy, especially if investments are made to improve technologies for measuring ZPP in field conditions. This will be a challenge, but the larger challenge is to find strategies to improve iron status where health systems are poor-or to improve the health systems. While we seek ways to provide safe oral supplements to treat iron deficiency in environments like Zanzibar, we should not lose sight of the greater need to find more feasible and integrated strategies to prevent the intractable problem of iron deficiency in young children.
